<DOC>
	<DOC>NCT00867815</DOC>
	<brief_summary>The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.</brief_summary>
	<brief_title>PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)</brief_title>
	<detailed_description>Collected data will be compared to historic data of the same participant in case-crossover design.</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy, Ischemic</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Sudden visual loss in 1 eye within 45 days before entry to the study History of erectile dysfunction at least 1 year prior to study enrollment At least 1 dose of PDE5 inhibitor(s) taken within a year prior to the onset of loss of vision Age 40 years or older History of multiple sclerosis or optic neuritis Evidence of temporal arteritis History of vasculitis or collagen vascular disease Previous history of NAION</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-arteritic Anterior Ischemic Optic Neuropathy</keyword>
	<keyword>NAION</keyword>
	<keyword>PDE5 inhibitors</keyword>
	<keyword>vardenafil</keyword>
	<keyword>Levitra</keyword>
	<keyword>sildenafil</keyword>
	<keyword>Viagra</keyword>
	<keyword>Tadalafil</keyword>
	<keyword>Cialis</keyword>
	<keyword>acute vision loss</keyword>
	<keyword>vision loss</keyword>
	<keyword>blurred vision</keyword>
	<keyword>optic neuropathy</keyword>
	<keyword>erectile dysfunction.</keyword>
</DOC>